Anika Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Anika Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-06-30 was 0.00 shares, a 100.00% decline year-over-year.
- Anika Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-03-31 was 0.00 shares, a 100.00% decline year-over-year.
- Anika Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2024-12-31 was 0.00 shares.
- Anika Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2024-09-30 was 0.00 shares.
- Anika Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 0.00 shares, a 100.00% decline from fiscal 2024.
- Anika Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 3.56K shares, a 74.83% increase from fiscal 2023.
- Anika Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 2.03K shares, a 369.75% increase from fiscal 2022.
- Anika Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 433.00 shares, a 98.62% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2025-12-31 | 0.00 shares 10-K · filed 2026-03-03 | |
| 2025-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-05 | 0.00 shares derived: sum of 4 quarters · filed 2025-11-05 |
| 2025-03-31 | 0.00 shares 10-Q · filed 2025-05-09 | 2.47K shares derived: sum of 4 quarters · filed 2025-05-09 |
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | 3.56K shares 10-K · filed 2025-03-17 |
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | 3.56K shares derived: sum of 4 quarters · filed 2024-11-04 |
| 2024-06-30 | 2.47K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 3.56K shares derived: sum of 4 quarters · filed 2024-08-08 |
| 2024-03-31 | 1.09K shares 10-Q · filed 2024-05-08 | 2.49K shares derived: sum of 4 quarters · filed 2024-05-08 |
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | 2.03K shares 10-K · filed 2024-03-15 |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | 2.03K shares derived: sum of 4 quarters · filed 2023-11-03 |
| 2023-06-30 | 1.40K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | 2.03K shares derived: sum of 4 quarters · filed 2023-08-08 |
| 2023-03-31 | 637.00 shares 10-Q · filed 2023-05-09 | 633.00 shares derived: sum of 4 quarters · filed 2023-05-09 |
| 2022-12-31 | -4.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | 433.00 shares 10-K · filed 2023-03-16 |
| 2022-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | 4.05K shares derived: sum of 4 quarters · filed 2022-11-09 |
| 2022-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | |
| 2022-03-31 | 437.00 shares 10-Q · filed 2022-05-06 | |
| 2021-12-31 | 3.62K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | 31.47K shares 10-K · filed 2022-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |